NCT01331213View on ClinicalTrials.gov

Pregabalin on Colonic Motor and Sensory Function in Constipation Predominant Irritable Bowel Syndrome

PHASE4CompletedINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

April 30, 2011

Primary Completion Date

February 28, 2013

Study Completion Date

February 28, 2013

Conditions
Irritable Bowel Syndrome
Interventions
DRUG

Pregabalin

FDA approved medication (capsules) at 200mg dose.

DRUG

Placebo

Placebo capsules

Trial Locations (1)

55905

Mayo Clinic in Rochester, Rochester

Sponsors

Lead Sponsor

Mayo Clinic
All Listed Sponsors
collaborator

National Center for Research Resources (NCRR)

NIH

lead

Mayo Clinic

OTHER

NCT01331213 - Pregabalin on Colonic Motor and Sensory Function in Constipation Predominant Irritable Bowel Syndrome | Biotech Hunter | Biotech Hunter